Net Loss Per Share Attributable to Common Stockholders (Tables)

12 Months Ended

Dec. 31, 2021

Earnings Per Share [Abstract]

Weighted-Average Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share as They Had Anti-Dilutive Effect

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect:

	Year Ended December 31,
	2021		2020
Options to purchase common stock		1,042,877		766,638
Contingently issuable common stock prior to exchange of    Vaccinex Products, LP units		557,029		1,164,791
Contingently issuable common stock prior to exchange of    VX3 units		612,876		1,318,797